DOI: 10.1302/1358-992x.2024.2.063 ISSN: 1358-992X
HIPGEN: A PHASE III STUDY ON PLACENTAL CELL THERAPY FOR IMPROVING MUSCLE REGENERATION IN HIP FRACTURE PATIENTS
T. WinklerThe HIPGEN study funded under EU Horizon 2020 (Grant 7792939) has the aim to investigate the potential of the first regenerative cell therapy for the improvement of recovery after muscle injury in hip fracture patients. For this aim we intramuscularly injected placental derived mesenchymal stromal cells during hip fracture arthroplasty. Despite not having reached the primary endpoint, which was the Short Physical Performance Battery, we could observe an increase in abductor muscle strength and a faster return to balance looking at symmetry in insole measurements during follow up.